Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Receivables - Other (2022 - 2025)

Historic Receivables - Other for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q3 2025 value amounting to $100000.0.

  • Amylyx Pharmaceuticals' Receivables - Other changed 0.0% to $100000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $100000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $100000.0 for FY2024, which is 8000.0% down from last year.
  • As of Q3 2025, Amylyx Pharmaceuticals' Receivables - Other stood at $100000.0, which was down 0.0% from $100000.0 recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Receivables - Other registered a high of $800000.0 during Q2 2023, and its lowest value of $100000.0 during Q3 2023.
  • For the 4-year period, Amylyx Pharmaceuticals' Receivables - Other averaged around $258333.3, with its median value being $100000.0 (2023).
  • In the last 5 years, Amylyx Pharmaceuticals' Receivables - Other changed by 0.0% in 2023 and then plummeted by 8750.0% in 2024.
  • Over the past 4 years, Amylyx Pharmaceuticals' Receivables - Other (Quarter) stood at $500000.0 in 2022, then changed by 0.0% to $500000.0 in 2023, then plummeted by 80.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • Its Receivables - Other stands at $100000.0 for Q3 2025, versus $100000.0 for Q2 2025 and $100000.0 for Q1 2025.